241 related articles for article (PubMed ID: 18068683)
1. Unique MAP Kinase binding sites.
Akella R; Moon TM; Goldsmith EJ
Biochim Biophys Acta; 2008 Jan; 1784(1):48-55. PubMed ID: 18068683
[TBL] [Abstract][Full Text] [Related]
2. The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation.
Bellon S; Fitzgibbon MJ; Fox T; Hsiao HM; Wilson KP
Structure; 1999 Sep; 7(9):1057-65. PubMed ID: 10508788
[TBL] [Abstract][Full Text] [Related]
3. Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1.
Slack DN; Seternes OM; Gabrielsen M; Keyse SM
J Biol Chem; 2001 May; 276(19):16491-500. PubMed ID: 11278799
[TBL] [Abstract][Full Text] [Related]
4. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
5. Sequence determinants of a specific inactive protein kinase conformation.
Hari SB; Merritt EA; Maly DJ
Chem Biol; 2013 Jun; 20(6):806-15. PubMed ID: 23790491
[TBL] [Abstract][Full Text] [Related]
6. Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically.
Chen P; Hutter D; Yang X; Gorospe M; Davis RJ; Liu Y
J Biol Chem; 2001 Aug; 276(31):29440-9. PubMed ID: 11387337
[TBL] [Abstract][Full Text] [Related]
7. A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates.
Zhang J; Zhou B; Zheng CF; Zhang ZY
J Biol Chem; 2003 Aug; 278(32):29901-12. PubMed ID: 12754209
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of inhibitor selectivity in MAP kinases.
Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
[TBL] [Abstract][Full Text] [Related]
9. Docking interactions induce exposure of activation loop in the MAP kinase ERK2.
Zhou T; Sun L; Humphreys J; Goldsmith EJ
Structure; 2006 Jun; 14(6):1011-9. PubMed ID: 16765894
[TBL] [Abstract][Full Text] [Related]
10. Kinetic mechanism and ATP-binding site reactivity of p38gamma MAP kinase.
Fox T; Fitzgibbon MJ; Fleming MA; Hsiao HM; Brummel CL; Su MS
FEBS Lett; 1999 Nov; 461(3):323-8. PubMed ID: 10567720
[TBL] [Abstract][Full Text] [Related]
11. Selectivity of docking sites in MAPK kinases.
Bardwell AJ; Frankson E; Bardwell L
J Biol Chem; 2009 May; 284(19):13165-73. PubMed ID: 19196711
[TBL] [Abstract][Full Text] [Related]
12. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution.
Wang Z; Harkins PC; Ulevitch RJ; Han J; Cobb MH; Goldsmith EJ
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2327-32. PubMed ID: 9122194
[TBL] [Abstract][Full Text] [Related]
13. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases.
Kampen GT; Stafford S; Adachi T; Jinquan T; Quan S; Grant JA; Skov PS; Poulsen LK; Alam R
Blood; 2000 Mar; 95(6):1911-7. PubMed ID: 10706854
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.
Pargellis C; Tong L; Churchill L; Cirillo PF; Gilmore T; Graham AG; Grob PM; Hickey ER; Moss N; Pav S; Regan J
Nat Struct Biol; 2002 Apr; 9(4):268-72. PubMed ID: 11896401
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction. MAP kinase signaling specificity.
Weston CR; Lambright DG; Davis RJ
Science; 2002 Jun; 296(5577):2345-7. PubMed ID: 12089430
[No Abstract] [Full Text] [Related]
16. Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions.
Tanoue T; Maeda R; Adachi M; Nishida E
EMBO J; 2001 Feb; 20(3):466-79. PubMed ID: 11157753
[TBL] [Abstract][Full Text] [Related]
17. X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.
Kuglstatter A; Ghate M; Tsing S; Villaseñor AG; Shaw D; Barnett JW; Browner MF
Bioorg Med Chem Lett; 2010 Sep; 20(17):5217-20. PubMed ID: 20655210
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b.
Chang CI; Xu BE; Akella R; Cobb MH; Goldsmith EJ
Mol Cell; 2002 Jun; 9(6):1241-9. PubMed ID: 12086621
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of PTP-SL/PTPBR7 catalytic domain: implications for MAP kinase regulation.
Szedlacsek SE; Aricescu AR; Fulga TA; Renault L; Scheidig AJ
J Mol Biol; 2001 Aug; 311(3):557-68. PubMed ID: 11493009
[TBL] [Abstract][Full Text] [Related]
20. Active mutants of the human p38alpha mitogen-activated protein kinase.
Diskin R; Askari N; Capone R; Engelberg D; Livnah O
J Biol Chem; 2004 Nov; 279(45):47040-9. PubMed ID: 15284239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
